Nuveen Asset Management, LLC Tcr2 Therapeutics Inc. Transaction History

Nuveen Asset Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.11 - $2.94 $358,012 - $498,841	-169,674 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.4 - $4.71 $142,286 - $279,237	59,286 Added 53.71%	169,674 $467,000
Q4 2021 Feb 14, 2022	SELL	$4.58 - $8.34 $47,719 - $86,894	-10,419 Reduced 8.62%	110,388 $511,000
Q3 2021 Nov 12, 2021	BUY	$8.44 - $18.35 $34,122 - $74,189	4,043 Added 3.46%	120,807 $1.21 Million
Q2 2021 Aug 16, 2021	SELL	$16.41 - $24.71 $24,253 - $36,521	-1,478 Reduced 1.25%	116,764 $1.92 Million
Q1 2021 May 17, 2021	SELL	$20.38 - $34.07 $399,244 - $667,431	-19,590 Reduced 14.21%	118,242 $2.61 Million
Q4 2020 Feb 16, 2021	BUY	$19.0 - $32.63 $486,495 - $835,491	25,605 Added 22.82%	137,832 $4.26 Million
Q3 2020 Nov 16, 2020	BUY	$13.1 - $20.69 $417,143 - $658,831	31,843 Added 39.61%	112,227 $2.28 Million
Q2 2020 Aug 14, 2020	BUY	$6.51 - $16.85 $281,297 - $728,088	43,210 Added 116.24%	80,384 $1.24 Million
Q1 2020 May 14, 2020	BUY	$6.01 - $16.01 $739 - $1,969	123 Added 0.33%	37,174 $287,000
Q4 2019 Feb 14, 2020	BUY	$12.17 - $17.88 $85,445 - $125,535	7,021 Added 23.38%	37,051 $530,000
Q3 2019 Nov 14, 2019	BUY	$10.15 - $19.53 $304,804 - $586,485	30,030 New	30,030 $451,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.